{
  "outcomes_metadata": {
    "timestamp": "2025-10-02T18:28:51.182787",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "consolidation_type": "outcomes",
    "data_split": "test",
    "total_unique_outcomes": 97,
    "source_countries": [
      "AT",
      "BE",
      "CZ",
      "DE",
      "DK",
      "EN",
      "ES",
      "EU",
      "FR",
      "IT",
      "NL",
      "PO",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        "overall survival (OS)",
        "all-cause mortality",
        "mortality",
        "HCC-related mortality",
        "liver-related mortality",
        "long-term survival",
        "median survival (by HCC stage)",
        "improved survival",
        "survival",
        "progression-free survival (PFS)",
        "progression-free survival (PFS; RECIST 1.1)",
        "progression-free survivorship",
        "time to progression (TTP)",
        "time to progression",
        "time-to-progression",
        "time to progression of the tumor",
        "time to symptomatic progression (TTSP)",
        "time to symptom progression",
        "time to deterioration",
        "time to patient-reported impairment of quality of life (EORTC QLQ-C30)",
        "time to patient-reported impairment of quality of life (EORTC QLQ-HCC18)",
        "time to patient-reported impairment of quality of life (EORTC QLQ-C30 functional role subscale)",
        "time to response",
        "duration of response (DoR)",
        "duration of response (DoR; time from partial or complete response to disease progression or exit)",
        "disease recurrence",
        "recurrence",
        "recurrence detection",
        "disease control rate (DCR)",
        "disease control rate (DCR; mRECIST)",
        "disease control",
        "clinical benefit rate (CBR)",
        "therapeutic efficacy",
        "success rate (downstaging/bridging)",
        "local tumour control",
        "tumour spread (TNM system)",
        "prognosis (assessed by diameter of largest tumour and number of tumours in the liver)",
        "extrahepatic tumour presence",
        "microinvasion",
        "tumour invasion in larger portal branches",
        "distant metastases",
        "tumour growth",
        "tumour reduction",
        "minor response (reduction of tumour size by 25 to 50%)",
        "stable disease (SD)",
        "stable disease (for at least 16 weeks)",
        "partial response (PR)",
        "partial response",
        "complete response (CR)",
        "complete remission",
        "objective response rate (ORR)",
        "objective response",
        "objective tumour response",
        "tumor response rate",
        "tumour response rate",
        "response rates",
        "response rates (RECIST criteria for locoregional therapies)",
        "response rates (mRECIST for systemic therapy)",
        "response rates (RECIS systems for systemic therapy)",
        "mRECIST response",
        "response assessment (multiphase computed tomography with contrast)",
        "response assessment (magnetic resonance imaging with contrast)",
        "progression assessment (BCLC assessment system)",
        "BCLC staging system",
        "Child-Pugh score",
        "Child-Pugh scale",
        "MELD score",
        "performance status",
        "Eastern Cooperative Oncology Group Performance Status (ECOG PS)",
        "severity of underlying liver disease"
      ],
      "response_measures": [
        "objective response rate (ORR; percentage of patients with partial or complete response; RECIST 1.1)",
        "objective response rate (ORR; percentage of patients with partial or complete response; modified RECIST for liver disease, mRECIST)",
        "number needed to treat (NNT)",
        "number needed to harm (NNH)"
      ],
      "progression_measures": [
        "progression-free survival (PFS; time from randomisation to tumour progression defined by RECIST 1.1 or death from any cause)",
        "time to tumour progression",
        "time to progression (TTP)",
        "progression-free survival (RECIST 1.1)"
      ]
    },
    "safety": {
      "adverse_events": [
        "adverse events (general)",
        "adverse reactions (general)",
        "adverse events (graded by National Cancer Institute)",
        "adverse events (grade 3 or higher)",
        "adverse reactions of grade 3 or higher",
        "adverse events (Grade ≥ 3)",
        "serious adverse events",
        "serious adverse reactions (grade 3/4)",
        "serious complications",
        "complications",
        "complication incidence",
        "post-treatment complications",
        "long-term treatment-related complications",
        "intraoperative complications",
        "perioperative mortality",
        "postoperative softening",
        "gallbladder abscess",
        "bleeding",
        "tumour haemorrhage",
        "significant haemorrhagic events",
        "significant thromboembolic events",
        "thrombosis of the venae portae",
        "thrombosis of the vena cavae main stem",
        "portal vein thrombosis",
        "needle tract seeding",
        "secondary cancer",
        "liver failure",
        "hepatotoxicity",
        "liver-related morbidity",
        "morbidity",
        "nutrition (EORTC QLQ-HCC18)",
        "loss of appetite",
        "decreased appetite",
        "weight loss",
        "pain (EORTC QLQ-HCC18)",
        "pain (EORTC QLQ-C30)",
        "pain",
        "abdominal pain",
        "abdominal swelling (EORTC QLQ-HCC18)",
        "jaundice (EORTC QLQ-HCC18)",
        "fever (EORTC QLQ-HCC18)",
        "fever",
        "fatigue (EORTC QLQ-HCC18)",
        "fatigue",
        "nausea",
        "diarrhoea",
        "hand-foot skin reaction",
        "hand feeding reactions",
        "skin rash",
        "rash",
        "skin desquamation",
        "desquamation",
        "alopecia",
        "hypocalcaemia",
        "increased ALT activity",
        "ALT increase",
        "AST increase",
        "creatinine increase",
        "laboratory haematological testing",
        "laboratory biochemical testing",
        "urinalysis",
        "electrocardiography",
        "QTc prolongation",
        "hypertension",
        "hypothyroidism",
        "dyspnoea",
        "pleural effusion",
        "cough",
        "back pain",
        "limb pain",
        "joint pain",
        "headache",
        "shortness of breath",
        "constipation",
        "abdominal swelling",
        "body image (EORTC QLQ-HCC18)",
        "role functioning (EORTC QLQ-C30)",
        "lymphoedema",
        "rebleeding",
        "varicose vein bleeding",
        "hepatic encephalopathy (grade > 1 on the New Haven criteria)",
        "hypersensitivity to monitoring",
        "fatal adverse events",
        "treatment-related deaths",
        "drug discontinuation due to adverse events",
        "dose modification due to adverse events",
        "adverse events leading to discontinuation"
      ],
      "serious_events": [
        "serious adverse events",
        "serious adverse reactions (grade 3/4)",
        "serious complications",
        "grade 5 adverse events",
        "treatment-related deaths",
        "fatal adverse events"
      ],
      "discontinuations": [
        "adverse events leading to discontinuation",
        "drug discontinuation due to adverse events",
        "dose modification due to adverse events"
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        "EORTC QLQ-C30",
        "EORTC QLQ-HCC18",
        "EORTC QLQ-LC13",
        "EQ-5D",
        "EQ-5D-3L",
        "EQ-5D-5L",
        "EQ-5D VAS",
        "EQ VAS (Euro QoL visual analogue scale)",
        "European Quality of Life – 5 Dimensions Visual Analogue Scale (EQ-5D VAS)",
        "FACT-G (Functional Assessment of Cancer Therapy – General)",
        "FACT-G",
        "FACT-Hep",
        "visual analogue scale",
        "overall quality of life (measured with a validated and reliable instrument)"
      ],
      "functional_status": [
        "health status",
        "global health status",
        "function scales of EORTC QLQ-C30",
        "function scales of EORTC QLQ-HCC18",
        "role functioning (EORTC QLQ-C30)",
        "performance status",
        "Eastern Cooperative Oncology Group Performance Status (ECOG PS)"
      ],
      "symptom_measures": [
        "pain (EORTC QLQ-HCC18)",
        "pain (EORTC QLQ-C30)",
        "fatigue (EORTC QLQ-HCC18)",
        "jaundice (EORTC QLQ-HCC18)",
        "fever (EORTC QLQ-HCC18)",
        "abdominal swelling (EORTC QLQ-HCC18)",
        "nutrition (EORTC QLQ-HCC18)",
        "body image (EORTC QLQ-HCC18)",
        "symptoms",
        "time to patient-reported impairment of quality of life (EORTC QLQ-C30)",
        "time to patient-reported impairment of quality of life (EORTC QLQ-HCC18)",
        "time to patient-reported impairment of quality of life (EORTC QLQ-C30 functional role subscale)",
        "deterioration in patient quality of life (based on EORTC QLQ-C30)",
        "deterioration in patient quality of life (based on EORTC QLQ-HCC18)"
      ]
    },
    "economic": {
      "cost_effectiveness": [
        "cost-effectiveness (incremental cost-effectiveness ratio, ICER)",
        "cost-effectiveness analysis",
        "cost-benefit analysis"
      ],
      "utilities": [
        "quality-adjusted life years (QALYs)",
        "quality of life weights",
        "health state utility values"
      ],
      "resource_utilization": [
        "length of hospital stay",
        "resource utilization"
      ]
    },
    "other": {
      "exploratory_endpoints": [
        "pharmacokinetic parameters",
        "plasma pharmacokinetics lenvatinib exposure parameters",
        "false positives",
        "success rate (downstaging/bridging)",
        "recurrence detection",
        "prognosis (assessed by diameter of largest tumour and number of tumours in the liver)",
        "extrahepatic tumour presence",
        "microinvasion",
        "tumour invasion in larger portal branches",
        "distant metastases",
        "tumour growth",
        "response assessment (multiphase computed tomography with contrast)",
        "response assessment (magnetic resonance imaging with contrast)"
      ],
      "biomarkers": [
        "blood and tumour biomarkers"
      ]
    }
  }
}